Be Proactive, Not Reactive: Updated Strategies for Optimal ADPKD Management and Better Outcomes
This activity is supported by an independent educational grant from Otsuka America Pharmaceutical, Inc.
Click Here to Manage Email Alerts
Overview
Provider Statement
This activity is jointly provided by Medical Education Resources and CMEology.
Support Statement
This activity is supported by an independent educational grant from Otsuka America Pharmaceutical, Inc.
Target Audience
This activity is designed for nephrology healthcare providers as well as other clinicians who see patients at risk for ADPKD.
Statement of Need
Autosomal dominant polycystic kidney disease (ADPKD) is the most common genetic renal disorder, and the unmet needs associated with ADPKD are among the most extensive of all renal diseases. ADPKD is often identified late or treatment is delayed in some patient populations. In younger patients, early manifestations of ADPKD are significant, such as intracranial aneurysm and polycystic liver disease. If hypertension is not controlled early, renal and nonrenal manifestations often worsen. Young adults with ADPKD are at a higher risk of cardiovascular morbidity and mortality. Patients who are older are often under-treated, even though recent data suggest disease-modifying therapy continues to benefit certain patients over 55 years old. Finally, profound health disparities among Black and Hispanic patients with ADPKD call for strategies to address the needs of these populations. This activity will enhance knowledge in the diagnosis, assessment of progression risk, and ongoing management of ADPKD, highlighting developing views on treatment in patients benefiting from proactive diagnosis and management.
Learning Objectives
Upon completion of the educational activity, participants should be able to:
- Identify strategies to be proactive in the management of younger patients with ADPKD.
- Discuss the importance of total kidney volume assessment and early management even when eGFR is stable.
- Apply proactive strategies to recognize and address disparities in the management of African American and Hispanic patients with ADPKD.
- Explain why genetic testing alone is inadequate for ADPKD management and prognostication.
Faculty
Neera Dahl, MD, PhD
Senior Associate Consultant
Director, Mayo PKD Center of Excellence
Mayo Clinic
Rochester, Minnesota
Meyeon Park, MD, MAS
Associate Professor of Medicine
Director, Polycystic Kidney Disease Center of Excellence
University of California San Francisco
San Francisco, California
Accreditation
In support of improving patient care, this activity has been planned and implemented by Medical Education Resources (MER) and CMEology. MER is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the health care team.
Credit Designation
Medical Education Resources designates this enduring material for a maximum of 1.5 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Medical Education Resources designates this enduring activity for a maximum of 1.5 ANCC nursing contact hours. Nurses will be awarded contact hours upon successful completion of the activity.
Medical Education Resources is a provider of continuing nursing education by the California Board of Registered Nursing, Provider #CEP 12299, for 1.5 contact hours.
How to Participate in This Activity and Obtain CE Credit
A statement of credit will be issued only upon receipt of a completed activity evaluation form and a completed posttest.
Disclosures
Medical Education Resources insures balance, independence, objectivity, and scientific rigor in all our educational activities. In accordance with this policy, MER identifies relevant financial relationships with its instructors, content managers, and other individuals who are in a position to control the content of an activity. Reported relevant financial relationships are mitigated by MER to ensure that all scientific research referred to, reported, or used in a CE activity conforms to the generally accepted standards of experimental design, data collection, and analysis. MER is committed to providing learners with high-quality CE activities that promote improvements or quality in health care and not the business interest of an ineligible company.
The faculty reported the following financial relationships with ineligible companies whose products or services may be mentioned in this activity:
Faculty reports the following relationship(s)
Neera Dahl, MD, PhD
Consulting Fees: Natera, Otsuka America Pharmaceutical, Inc.
Grant/Research Support: Janssen, Reata Pharmaceuticals, Inc., Vertex Pharmaceuticals Incorporated
Speakers Bureau: Unbranded speakers bureau for Otsuka America Pharmaceutical, Inc.
Meyeon Park, MD, MAS
Grants/Research Support: Otsuka America Pharmaceutical, Inc.
Consulting Fees (eg, Advisory boards): Natera, Inc. and Otsuka America Pharmaceutical, Inc.
Reviewers report the following relevant relationship(s)
CMEology planners have no relationships to disclose.
MER content reviewers have no relationships to disclose.
Disclaimer
The content and views presented in this educational activity are those of the authors and do not necessarily reflect those of Medical Education Resources, CMEology, and/or Otsuka America Pharmaceutical, Inc. The authors have disclosed if there is any discussion of published and/or investigational uses of agents that are not indicated by the FDA in their presentations. Before prescribing any medicine, primary references and full prescribing information should be consulted. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications on dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities. The information presented in this activity is not meant to serve as a guideline for patient management.
Copyright Statement
All materials prepared in connection with this activity shall be the property of CMEology and Medical Education Resources, unless specified otherwise, and shall be reviewed and filed by Medical Education Resources for accreditation purposes.
CME Questions?
For questions about this activity, please contact CMEology at: info@cmeology.org or Medical Education Resources at: http://cmepartner.org/contact.